Credit Suisse analyst Vamil Divan maintained a Hold rating on Alder Biopharmaceuticals (ALDR) yesterday and set a price target of $17. The company’s shares closed yesterday at $11.20, close to its 52-week low of $10.45.
According to TipRanks.com, Divan is a 1-star analyst with an average return of -3.2% and a 42.9% success rate. Divan covers the Healthcare sector, focusing on stocks such as Aimmune Therapeutics, Johnson & Johnson, and Merck & Company.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alder Biopharmaceuticals with a $23.33 average price target, which is a 108.3% upside from current levels. In a report issued on December 12, Mizuho Securities also maintained a Hold rating on the stock with a $15 price target.
.
See today’s analyst top recommended stocks >>
Based on Alder Biopharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $60.92 million. In comparison, last year the company had a GAAP net loss of $59.57 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alder Biopharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company, which discovers, develops, and commercializes various therapeutic antibodies. Its product portfolio includes ALD1910, a preclinical product candidate also in development as a migraine prevention therapy.
